Payment overview · 2025
General Payments
$567.71
20 reported records · 13 companies
Healthcare provider profile · identity verified
Christopher Allan Kellogg, DO
Allopathic & Osteopathic Physicians|Internal Medicine · WATERTOWN, NY · NPI 1598260119
Verified facts
What the public records show
CMS Open Payments records show Christopher Allan Kellogg, DO received $567.71 in general payments during 2025 across 20 reported records.
Madrigal Pharmaceuticals accounted for 39.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 332 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 332 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $226.11 | 39.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $60.03 | 10.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.45 | 7.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $39.00 | 6.9% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $35.49 | 6.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.17 | 5.8% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $25.26 | 4.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.46 | 4.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.90 | 3.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.41 | 3.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.82 | 3.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.08 | 2.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.53 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $567.71 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $226.11 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $60.03 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.45 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $38.16 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $25.26 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.46 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $18.25 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 332 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 29 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
332 | 52 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 29 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 35 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
332 | 52 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 658 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 442 | 122 |
| Levothyroxine Sodium | Levothyroxine Sodium | 376 | 95 |
| Losartan Potassium | Losartan Potassium | 372 | 97 |
| Gabapentin | Gabapentin | 339 | 65 |
| Omeprazole | Omeprazole | 334 | 107 |
| Eliquis | Apixaban | 332 | 52 |
| Lisinopril | Lisinopril | 287 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 255 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 255 | 90 |
| Sertraline Hcl | Sertraline Hcl | 231 | 48 |
| Furosemide | Furosemide | 230 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 211 | 51 |
| Spironolactone | Spironolactone | 188 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 187 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 165 | 42 |
| Famotidine | Famotidine | 164 | 37 |
| Metformin Hcl | Metformin Hcl | 158 | 52 |
| Mirtazapine | Mirtazapine | 154 | 30 |
| Allopurinol | Allopurinol | 152 | 36 |
| Trazodone Hcl | Trazodone Hcl | 144 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 40 |
| Ozempic | Semaglutide | 143 | 35 |
| Potassium Chloride | Potassium Chloride | 139 | 33 |
| Prednisone | Prednisone | 139 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 129 | 23 |
| Simvastatin | Simvastatin | 127 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 116 | 49 |
| Ropinirole Hcl | Ropinirole Hcl | 115 | 17 |
| Jardiance | Empagliflozin | 114 | 29 |
| Torsemide | Torsemide | 113 | 22 |
| Buspirone Hcl | Buspirone Hcl | 112 | 27 |
| Xarelto | Rivaroxaban | 104 | 23 |
| Alprazolam | Alprazolam | 98 | 19 |
| Donepezil Hcl | Donepezil Hcl | 96 | 11 |
| Tramadol Hcl | Tramadol Hcl | 90 | 18 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 86 | 13 |
| Montelukast Sodium | Montelukast Sodium | 86 | 26 |
| Ezetimibe | Ezetimibe | 82 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 21 |
| Chlorthalidone | Chlorthalidone | 75 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 19 |
| Finasteride | Finasteride | 72 | 14 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 20 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 67 | 12 |
| Carvedilol | Carvedilol | 67 | 21 |
| Bupropion Xl | Bupropion Hcl | 65 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 13 |
| Divalproex Sodium | Divalproex Sodium | 63 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 15 |
| Alendronate Sodium | Alendronate Sodium | 57 | 18 |
| Metformin Hcl Er | Metformin Hcl | 54 | 24 |
| Trulicity | Dulaglutide | 54 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 53 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 53 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 53 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 50 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 16 |
| Meloxicam | Meloxicam | 49 | 13 |
| Olanzapine | Olanzapine | 48 | suppressed |
| Celecoxib | Celecoxib | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | suppressed |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Azithromycin | Azithromycin | 43 | 22 |
| Creon | Lipase/Protease/Amylase | 43 | suppressed |
| Clonazepam | Clonazepam | 42 | suppressed |
| Glimepiride | Glimepiride | 42 | 14 |
| Latanoprost | Latanoprost | 42 | suppressed |
| Lactulose | Lactulose | 41 | suppressed |
| Lorazepam | Lorazepam | 41 | 13 |
| Fluconazole | Fluconazole | 40 | 30 |
| Pregabalin | Pregabalin | 40 | 11 |
| Atenolol | Atenolol | 39 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 37 | 11 |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Neupro | Rotigotine | 36 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 35 | suppressed |
| Synthroid | Levothyroxine Sodium | 35 | 13 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Nystatin | Nystatin | 34 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 33 | suppressed |
| Calcitriol | Calcitriol | 33 | suppressed |
| Klor-Con M10 | Potassium Chloride | 33 | 11 |
| Farxiga | Dapagliflozin Propanediol | 32 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 11 |
| Sucralfate | Sucralfate | 32 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 14 |
| Cimetidine | Cimetidine | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 25 | 20 |
| Irbesartan | Irbesartan | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | 11 |
| Risperidone | Risperidone | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 20 |
| Digoxin | Digoxin | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Teriflunomide | Teriflunomide | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 19 |
| Methenamine Hippurate | Methenamine Hippurate | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Cefdinir | Cefdinir | 21 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Levofloxacin | Levofloxacin | 21 | 19 |
| Haloperidol | Haloperidol | 20 | suppressed |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Amantadine | Amantadine Hcl | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | 13 |
| Prolia | Denosumab | 18 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 16 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 15 | suppressed |
| Levetiracetam Er | Levetiracetam | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 13 | suppressed |
| Deblitane | Norethindrone | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $567.71 · 20 records | Madrigal Pharmaceuticals | AIRSUPRA, BREZTRI, CAMZYOS, ELIQUIS, GEMTESA, Kerendia, MOUNJARO, NURTEC ODT, REXULTI, REZDIFFRA, TRELEGY ELLIPTA, VRAYLAR, Wegovy, XIFAXAN, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error